Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Type 2 Diabetes Mellitus
Phase PHASE3
Enrollment 600
Locations 132 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Placebo — Placebo is administered orally once daily.

Primary Outcomes

  • Change from baseline in Hemoglobin A1c (HbA1c) (Baseline to Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-08
Completion: 2028-05-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Placebo — Placebo is administered orally once daily.
Study Locations (132 sites)
Research Site, Little Rock, Arkansas 72205 United States
Research Site, Sacramento, California 95821 United States
Research Site, Aurora, Colorado 80045 United States
Research Site, DeLand, Florida 32720 United States
Research Site, Doral, Florida 33166 United States
Research Site, Ocoee, Florida 34761 United States
Research Site, Decatur, Georgia 30030 United States
Research Site, Potomac, Maryland 20854 United States
Research Site, Brooklyn, New York 11220 United States
Research Site, Cary, North Carolina 27518 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with T2DM for at least 90 days prior to screening * Stable treatment with background insulin and other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis. * Severe congestive heart failure (NYHA IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Conditions Obese Adults, BMI/Body Composition, Card...
Phase NA
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate whether a precision lifestyle medicine intervention can improve cardiometabolic health in Emirati adults aged 25 to 50 years living in Abu Dhabi with obesity (BMI 30-35 kg/m²) who have previously completed IFHAS screening. The study will also use IFHAS screening data to better understand participants' health profiles and the relationship between lifestyle factors and chronic diseases. The main questions it aims to answer are: * Does a precision lifestyle medicine program improve cardiometabolic biomarkers after an 18-week intervention? * Can IFHAS screening data be used to identify health risk profiles and support personalized lifestyle interventions for the Emirati population? Researchers will compare participants receiving the precision lifestyle medicine intervention with a propensity-matched control group receiving standard IFHAS care to determine whether the intervention leads to greater improvements in cardiometabolic health. Participants will: * Take part in an 18-week personalized lifestyle medicine program tailored to their health profile. * Attend study visits and complete health assessments over a total study period of 24 weeks. * Undergo cardiometabolic biomarker assessments before and after the intervention. * Complete questionnaires or assessments about their adherence to the lifestyle program and their experience with the precision lifestyle medicine clinic. * Provide biological samples to support the establishment of a biomarker repository for future research.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Precision Lifestyle Medicine Program — Participants receive an 18-week precision lifestyle medicine intervention based on individual IFHAS screening results and cardiometabolic risk stratification. The program includes personalized lifestyle recommendations and multidisciplinary clinical support focused on improving cardiometabolic health. Participants are followed for 24 weeks, with assessments conducted at baseline and post-intervention.
  • Other: Standard IFHAS Care — Participants receive standard IFHAS care without participation in the precision lifestyle medicine intervention. This group serves as a propensity score-matched comparison cohort.

Primary Outcomes

  • Change in Body Mass Index (BMI) (Baseline and Week 24)
  • Change in Cardiometabolic Composite Response (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-03
Completion: 2027-12-13
Eligibility
Age: 25 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Healthier Living Abu Dhabi
Collaborators: Abu Dhabi Public Health Centre
Principal Investigators:
  • Nicole Sirotin, MD (PRINCIPAL_INVESTIGATOR) - Institute for Healthier Living Abu Dhabi
Contact Information
Study Contact:
Erik Koornneef, PhD
+971500888594
e.koornneef@ihlad.ae
Leanne Cassidy, MSc
+971559168075
l.cassidy@ihlad.ae
Shamma Al Jneibi
026451700
s.aljneibi@ihlad.ae
Institute for Healthier Living
Interventions
  • Behavioral: Precision Lifestyle Medicine Program — Participants receive an 18-week precision lifestyle medicine intervention based on individual IFHAS screening results and cardiometabolic risk stratification. The program includes personalized lifestyle recommendations and multidisciplinary clinical support focused on improving cardiometabolic health. Participants are followed for 24 weeks, with assessments conducted at baseline and post-intervention.
  • Other: Standard IFHAS Care — Participants receive standard IFHAS care without participation in the precision lifestyle medicine intervention. This group serves as a propensity score-matched comparison cohort.
Study Locations (1 sites)
Institute for Healthier Living, Abu Dhabi, United Arab Emirates
Eligibility Criteria
Inclusion Criteria: * Emiratis residing in Abu Dhabi emirate * Aged 25-50 years * BMI 30-35 kg/m² * Thiqa cardholder * Previous participation in IFHAS screening * Able to provide informed consent * Participant in the Emirati Genome Programme * No weight-loss medications (e.g., Ozempic, Saxenda, Wegovy) within 3 months of enrollment. Exclusion Criteria: * Aged under 25 years or over 50 years of age * BMI range under 30 kg/m2 and over 35 kg/m2 * Taking weight loss medication such as GLP-1 drugs (Ozempic, Saxenda, Wegovy) * Active treatment for serious medical conditions (cancer, planned surgery, immunomodulation) * Transplant surgery within 12 months * Pregnancy * Surgery within 3 months prior to recruitment * Physical limitations preventing exercise participation * Current enrolment in other lifestyle intervention programs * Active psychiatric conditions, cognitive impairment, or mental health conditions affecting study participation * Contraindication to MRI or DEXA imaging, including severe claustrophobia or need for sedation.
Conditions Breast Cancer
Phase PHASE2
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The UNITY study is a prospective, single-arm, single-center, Phase II clinical trial conducted by Fudan University Shanghai Cancer Center. It aims to evaluate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) combined with ivonescimab in patients with hormone receptor-positive (HR+), HER2-negative recurrent or metastatic breast cancer. Approximately 53 patients will be enrolled. Eligible participants must have histologically confirmed advanced HR-positive breast cancer with HER2-low or HER2-ultralow expression. They must have experienced recurrence, metastasis, or disease progression after prior treatment with a CDK4/6 inhibitor (including in the adjuvant setting) and have received at most one line of systemic chemotherapy for advanced disease. The study permits the enrollment of patients with central nervous system (CNS) metastases. The primary endpoint is the Overall Response Rate (ORR). Key secondary endpoints include Clinical Benefit Rate (CBR), Overall Survival (OS), Progression-Free Survival (PFS), safety, and patient-reported quality of life (assessed using EORTC QLQ-C30 and QLQ-BR23). Exploratory endpoints will involve the analysis of biomarkers from tumor and blood samples, as well as PAM50 molecular subtyping and its correlation with survival outcomes. This study seeks to explore the efficacy and safety of Trastuzumab Deruxtecan in combination with ivonescimab for patients with HR-positive, HER2-negative recurrent or metastatic breast cancer, with a particular focus on the subpopulation with CNS metastases.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab Deruxtecan and ivonescimab — * Trastuzumab Deruxtecan (T-DXd): Administered at a dose of 5.4 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle. * Ivonescimab: Administered at a dose of 20 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle. Treatment for both agents will continue until disease progression or unacceptable toxicity.

Primary Outcomes

  • ORR (From treatment initiation until disease progression or death, assessed by RECIST v1.1., assessed up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-01
Completion: 2028-02-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Hongxia Wang
86-138196379
whx365@126.com
Ting Li
86-18121299346
Hongxia Wang, PHD
13524491606
whx365@126.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: Trastuzumab Deruxtecan and ivonescimab — * Trastuzumab Deruxtecan (T-DXd): Administered at a dose of 5.4 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle. * Ivonescimab: Administered at a dose of 20 mg/kg via intravenous (IV) infusion on Day 1 of each 21-day cycle. Treatment for both agents will continue until disease progression or unacceptable toxicity.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years, any gender. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 3. Histologically or cytologically confirmed Hormone Receptor-positive (HR+) and Human Epidermal Growth Factor Receptor 2 (HER2)-low or HER2-ultralow breast cancer, with evidence of locally recurrent or metastatic disease that is not amenable to curative-intent surgery or radiation therapy. * HR positivity is defined as Estrogen Receptor (ER) positive (≥1% positive cells) and/or Progesterone Receptor (PR) positive (≥1% positive cells). * HER2-low or HER2-ultralow expression is defined as HER2 (0 with staining), HER2 (1+), or HER2 (2+) by immunohistochemistry (IHC) with a negative in-situ hybridization (ISH) result. * Fulfillment of these criteria from any single pathological assessment is sufficient for eligibility. 4. Life expectancy of ≥ 3 months. 5. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). 6. History of recurrence or disease progression after prior treatment with a CDK4/6 inhibitor (including in the adjuvant setting). Patients have received a maximum of one line of chemotherapy for recurrent or metastatic disease. Recurrence or disease progression during or within 6 months after completion of neoadjuvant/adjuvant intravenous chemotherapy is counted as one line of therapy. 7. Patients with Central Nervous System (CNS) metastases are eligible. Ventriculoperitoneal shunt to relieve intracranial pressure or use of mannitol, corticosteroids, or anticonvulsants is permitted prior to the first dose. However, the dose of such medications must be stable for at least 1 week without an increase, and neurological symptoms must be stable without worsening for at least 1 week. (Priority will be given to the enrollment of patients with CNS metastases.) 8. Availability of an adequate tumor tissue sample for retrospective analysis of PD-L1 status. 9. Adequate organ function, defined as follows: * Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L; Platelets (PLT) ≥ 75 × 10⁹/L; Hemoglobin (Hb) ≥ 90 g/L (transfusion or medical support to meet this level is permitted). * Hepatic and Renal Function: Total Bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3 × ULN (≤ 5.0 × ULN in the presence of liver metastases); Blood Urea Nitrogen (BUN) or Serum Creatinine (Cr) ≤ 1.5 × ULN, or Creatinine Clearance ≥ 50 mL/min (calculated by Cockcroft-Gault formula). * Coagulation: Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN; Prothrombin Time (PT) ≤ 1.5 × ULN. * Cardiac: QT interval corrected by Fridericia's formula (QTcF) \< 470 ms for females and \< 450 ms for males on a 12-lead electrocardiogram (ECG); Left Ventricular Ejection Fraction (LVEF) ≥ 50% by echocardiogram. 10. Voluntary participation in the study with signed informed consent, and willingness to comply with study procedures and follow-up. Exclusion Criteria: 1. Confirmed leptomeningeal metastases by Magnetic Resonance Imaging (MRI) or lumbar puncture. 2. Prior treatment with anti-PD-1/PD-L1 or anti-VEGF agents, unless both of the following conditions are met: (1) The patient did not experience disease progression during treatment with the anti-PD-1/PD-L1 or anti-VEGF agent; and (2) The time from the last dose of the anti-PD-1/PD-L1 or anti-VEGF agent to the time of recurrence or disease progression is ≥ 3 months. 3. Presence of third-space fluid accumulation (e.g., massive pleural or peritoneal effusion) that cannot be controlled by drainage or other methods. 4. Receipt of whole-brain radiotherapy, chemotherapy, targeted biologic therapy, immunotherapy, surgery, or endocrine therapy within 2 weeks prior to the first dose of study drug. Bone-modifying agents for the treatment of bone metastases or prevention of osteoporosis are permitted. 5. Prior treatment with trastuzumab deruxtecan or any antibody-drug conjugate (ADC) containing a topoisomerase inhibitor. 6. Participation in another interventional drug clinical trial within 2 weeks prior to enrollment. Participation in non-interventional studies is allowed. 7. Major surgery or significant trauma within 4 weeks prior to randomization, or anticipation of the need for major surgery during the study. 8. Concurrent receipt of any other anti-cancer therapy. 9. History of other malignancies within the past 5 years, except for curatively treated cervical carcinoma in situ, cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, and papillary thyroid carcinoma. 10. History of any of the following cardiac conditions: (1) Myocardial infarction; (2) Congestive heart failure; (3) Any other cardiac condition judged by the investigator to be unsuitable for study participation. 11. Known history of hypersensitivity to any component of the study drugs. 12. History of immunodeficiency, including positive test for Human Immunodeficiency Virus (HIV), other acquired or congenital immunodeficiency diseases, or a history of organ transplantation. 13. Active hepatitis (Hepatitis B defined as HBsAg positive and HBV DNA ≥ 1000 IU/mL; Hepatitis C defined as HCV antibody positive and HCV RNA \> upper limit of normal). 14. History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening. 15. Clinically significant pulmonary-specific comorbidities, including but not limited to any underlying pulmonary disease (e.g., pulmonary embolism within 3 months prior to the study, severe asthma, severe COPD, restrictive lung disease, pleural effusion, etc.). 16. Uncontrolled infection requiring systemic antibiotic, antiviral, or antifungal therapy. 17. Clear history of neurological or psychiatric disorders, including epilepsy or dementia. 18. Pregnant or breastfeeding women; women of childbearing potential with a positive pregnancy test at baseline or who are unwilling to use effective contraceptive measures throughout the study period. 19. Presence of any concomitant disease that, in the investigator's judgment, could seriously compromise patient safety or interfere with completion of the study (including, but not limited to, uncontrolled severe hypertension, uncontrolled severe diabetes, active infection, etc.). 20. Any other condition for which the investigator considers the patient unsuitable for participation in this study.
Conditions Uncontrolled Asthma
Phase NA
Enrollment 540
Locations 20 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate whether GDMT can bring significant benefits to disease management in uncontrolled asthma patients receiving medium- to high-dose ICS-LABA. * The intervention period will be up to 48 weeks; * The frequency of follow-up is every 12 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Behavioral: Intervention group — The GDMT pathway targets physicians and specialized nurses for implementation. It ensures that physicians at intervention groups conduct standardized diagnosis and treatment following GDMT, and that specialized nurses deliver patient education and follow-up reminders according to GDMT. This is achieved through regular knowledge training, provision of a series of reminder/support tools, and a bi-weekly (every 12 weeks) monitoring, and feedback system for Key Performance Indicators (KPIs).

Primary Outcomes

  • Difference in the proportion of participants with a written diagnosis of "Severe Asthma" between the intervention and control groups at Week 24 (Week 24)
  • Difference in the annualized asthma exacerbation rate between the intervention and control groups at Week 48 (Week 48)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-05
Completion: 2028-04-30
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 540 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Principal Investigators:
  • Kewu Huang (PRINCIPAL_INVESTIGATOR) - Beijing Chao Yang Hospital
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Behavioral: Intervention group — The GDMT pathway targets physicians and specialized nurses for implementation. It ensures that physicians at intervention groups conduct standardized diagnosis and treatment following GDMT, and that specialized nurses deliver patient education and follow-up reminders according to GDMT. This is achieved through regular knowledge training, provision of a series of reminder/support tools, and a bi-weekly (every 12 weeks) monitoring, and feedback system for Key Performance Indicators (KPIs).
Study Locations (20 sites)
Research Site, Chengdu, 611130 China
Research Site, Chifeng, 024206 China
Research Site, Dongyang, 322100 China
Research Site, Hefei, 133500 China
Research Site, Hefei, 230041 China
Research Site, Hengyang, 421001 China
Research Site, Heze, 274099 China
Research Site, Jiaxing, 314001 China
Research Site, Langfang, 065000 China
Research Site, Meizhou, 514031 China
Eligibility Criteria
Inclusion Criteria: 1. Sign the informed consent form before any study-related procedures; 2. Age 18-75 years (inclusive) at Visit 0; 3. Have a written diagnosis of asthma for more than 6 months prior to Visit 0, and have evidence of reversible airflow limitation prior to Visit 0. Evidence of reversible airflow limitation includes: post-bronchodilator increase in Forced Expiratory Volume in 1 second (FEV1) of ≥12% and an absolute increase of ≥200 mL, or average daily diurnal Peak Expiratory Flow (PEF) variability \>10%, or an increase in FEV1 of ≥12% and an absolute increase of ≥200 mL compared to baseline after 4 weeks of treatment containing ICS, or a positive bronchial provocation test record. If no prior record exists, reversible airflow limitation must be confirmed and documented via a bronchodilator test during Visit 0; 4. Under the usage of MD/HD ICS-LABA; 5. Experienced one or more exacerbations within the past year; Exacerbation is defined as meeting any of the following criteria: 1. Use of systemic corticosteroids (or a temporary increase in the stable dose of baseline oral corticosteroids) for at least 3 days; a single injection of a depot long-acting corticosteroid can be considered equivalent to a 3-day course of systemic corticosteroids; 2. An emergency department or urgent care site visit for asthma (defined as being evaluated and treated in the emergency department or urgent care site for \< 24 hours) requiring the use of systemic corticosteroids for at least 3 days (as described above); 3. Hospitalization for asthma (defined as admission to a hospital and/or being evaluated and treated in a healthcare facility for ≥ 24 hours). Exclusion Criteria: 1. Previous written diagnosis as "Severe Asthma"; Diagnosis of Severe Asthma includes: severe asthma, or related diagnoses containing "severe asthma", or "bronchial asthma (severe)". 2. Imaging suggests the presence of bullae or cystic bronchiectasis; 3. Currently participating in other interventional studies; 4. Previous use of biologics for asthma treatment; 5. Using systemic glucocorticoids for other diseases; 6. History of respiratory tract infection within 4 weeks prior to Visit 0 (upper respiratory tract infections and lower respiratory tract infections); 7. Any significant disease or disorder (e.g., cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine/metabolic, malignant, psychiatric, or significant physical impairment, etc.) which, in the opinion of the investigator, may put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to comply with GDMT.
Conditions Nursing Home Resident, Skilled Nursing F...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test a behavioral health program (Interventions for Stressful Transitions in Later Life, InSTILL, for Individuals) for skilled nursing facility residents. The main questions it aims to answer is whether the program is program is feasible, satisfactory, and helpful. Participants will join 6 bi-weekly sessions of the InSTILL program. Participants will complete assessments at three timepoints (all) and a brief-exit interview.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Interventions for Stressful Transitions in Later Life (InSTILL) for Individuals — The Interventions for Stressful Transitions in Later Life (InSTILL) intervention is for skilled nursing facility residents experiencing elevated levels of psychological distress. The intervention is designed to improve life management skills and emotion regulation skill with the goal of reducing depression symptoms.

Primary Outcomes

  • Mean Total Score Treatment Credibility (After session 1 of intervention, an average of 1 week after baseline)
  • Mean Total Score Client Satisfaction Questionnaire (Post intervention, an average of 4 weeks after baseline)
  • Percentage of Eligible Participants Enrolled (Post intervention, an average of 4 weeks after baseline)
  • Percentage of Participants with Missing Data (4 weeks after post-intervention)
  • Attendance Rate (Post intervention, an average of 4 weeks after baseline)
  • Clinician Fidelity (Post intervention, an average of 4 weeks after baseline)
  • Number of Adverse Events (4 weeks after post-intervention)
  • Treatment Acceptability Survey (Post intervention, an average of 4 weeks after baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-17
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Principal Investigators:
  • Evan Plys, PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
BRISK Study Coordinator
617-643-9406
brisk@mgb.org
BRISK Study Coordinator
617-643-9406
brisk@mgb.org
Massachusetts General Hospital
Interventions
  • Behavioral: Interventions for Stressful Transitions in Later Life (InSTILL) for Individuals — The Interventions for Stressful Transitions in Later Life (InSTILL) intervention is for skilled nursing facility residents experiencing elevated levels of psychological distress. The intervention is designed to improve life management skills and emotion regulation skill with the goal of reducing depression symptoms.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
Eligibility Criteria
Inclusion Criteria: * Psychological distress, as indicated by a score Patient Health Questionnaire- 2 ≥ 2 OR Patient Health Questionnaire-9 ≥ 5 * 5+ chronic conditions based on Elixhauser Comorbidity Index * Aged ≥ 18 years * Able and willing to participate in the study Exclusion Criteria: * Intended length of SNF stay \< 7 days * More than mild cognitive impairment, as indicted by Brief Interview for Mental Status (BIMS) \<13 * Participant's roommate is already enrolled in study/intervention * High risk of suicide/active documented SI per the PHQ-9, item 9 or otherwise * Participation in newly initiated psychotherapy
Conditions Type 2 Diabetes Mellitus
Phase PHASE3
Enrollment 1200
Locations 209 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Semaglutide — Semaglutide is administered orally once daily.

Primary Outcomes

  • Change from baseline in Hemoglobin A1c (HbA1c) (Baseline to Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-06
Completion: 2028-05-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Semaglutide — Semaglutide is administered orally once daily.
Study Locations (209 sites)
Research Site, Birmingham, Alabama 35205 United States
Research Site, Mesa, Arizona 85213 United States
Research Site, Phoenix, Arizona 85016 United States
Research Site, Tempe, Arizona 85281 United States
Research Site, Covina, California 91723 United States
Research Site, Encinitas, California 92024 United States
Research Site, Garden Grove, California 92844 United States
Research Site, Loma Linda, California 92354 United States
Research Site, Long Beach, California 90807 United States
Research Site, Pomona, California 91768 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication(s) * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Increased risk of cardiovascular (CV) events defined by ≥1 of: documented coronary heart disease, peripheral arterial disease, ischemic cerebrovascular disease, or heart failure (NYHA II-III); or ≥2 CV risk factors * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * Type 1 Diabetes Mellitus (T1DM), secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper Gastrointestinal (GI) tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * Severe congestive heart failure (NYHA IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Conditions Schizophrenia, Treatment Resistant Depre...
Phase NA
Enrollment 700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The disruption of immune system is a key candidate in the pathogenesis of psychiatric disorders, especially those resistant to traditional treatments. Involving complex processes within the brain and peripheral immune system, inflammation may lead to imbalance of neurotransmitter systems and synaptic plasticity and directly contribute to the psychiatric symptoms observed in conditions such as depression, bipolar disorder (BD) and schizophrenia (SCZ). Studies show that treatment-resistant depression (TRD) is associated with elevated levels of inflammatory markers in the blood, which are linked to a lower response to conventional antidepressants. Interventions that modulate this inflammatory response, such as immunomodulatory treatments or therapies targeting pro-inflammatory cytokines, have demonstrated beneficial effects by reducing symptoms and improving patients' quality of life. A thorough understanding of the links between inflammation and treatment resistance therefore paves the way for innovative therapeutic strategies. These approaches could transform current practices by offering more personalized and effective solutions for patients suffering from chronic and resistant psychiatric disorders.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Biological: Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales — the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin

Primary Outcomes

  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in disease scale scores at the end of acute phase therapy (V3) (Up to 10 weeks)
  • Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). (Up to 10 weeks)
  • Changes from inclusion (V1) in biological parameters at the end of acute phase therapy (V3). (Up to 10 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-20
Completion: 2038-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier St Anne
Collaborators: GHU Paris Psychiatry & Neurosciences
Principal Investigators:
  • Anne-Cécile PETIT, MD, PhD (STUDY_DIRECTOR) - GHU Paris Psychiatry & Neurosciences
Contact Information
Study Contact:
Iolanda PALIMARU, MD
+33145658798
iolanda.palimaru@ghu-paris.fr
Cécile MICHEL
+331 80 52 70 19
cecile.bultez@ghu-paris.fr
GHU Paris - Psychiatrie et Neurosciences
Interventions
  • Biological: Blood sampling, lumbar puncture, stool sampling, skin microbiopsy and psychometrics scales — the biomarker research involves different biological sampling : blood, stool, cerebrospinal fluid, skin
Study Locations (1 sites)
GHU Paris - Psychiatrie et Neurosciences, Paris, 75014 France
Eligibility Criteria
Inclusion Criteria: * Patient aged ≥ 18 years old; * Patient suffering from a psychiatric disorder according to DSM-5 criteria; * Patient with drug-resistant disease according to the definition of the protocol * Patient starting a new treatment for his pathology; * Patient informed and having signed an informed consent; * Patient covered by the social security system. Exclusion Criteria: * Patient with major neurocognitive disorder diagnosed (dementia syndrome) * Pregnant, laboring, or breastfeeding female patients * Patient deprived of liberty by judicial or administrative decision. Patient in psychiatric care under constraints may be included. * For patients accepting the lumbar punction: patients who are unable to control themselves and are likely to engage in physical or violent behavior.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase NA
Enrollment 126
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer. FOP is the fear patients experience from the possibility that their cancer could grow, spread, or get worse. Managing FOP is a leading unmet concern of cancer patients. High levels of FOP are associated with distress, depression, and increased health care costs, despite this, access to resources to address FOP remain limited. The blended e-health intervention in this trial offers remote group sessions along with online sessions to help patients access the information. Session content incorporates values-based goal setting and skills practices to manage unhelpful beliefs about worry and promote helpful coping behaviors. The sessions may help patients recognize unhelpful thoughts and behaviors which reinforce worry. A blended e-health intervention may be an effective way to improve FOP in women with gynecologic or breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Triple

Interventions / Regimen

  • Other: Best Practice — Participate in Navigating Cancer Program
  • Other: Interview — Ancillary studies
  • Other: Supportive Care — Participate in Mindful Living Program
  • Other: Supportive Care — Complete skills practice
  • Other: Supportive Care — Receive access to videos and website
  • Other: Survey Administration — Ancillary studies
  • Behavioral: Telephone-Based Intervention — Receive check-in call

Primary Outcomes

  • Recruitment rate (Feasibility of enrollment) (Up to 18 months)
  • Attrition rate (Intervention feasibility) (Up to 6 weeks)
  • Percentage of Attendance/Sessions Completed (Up to 6 weeks)
  • System Usability Scale survey (Acceptability) (At week 6 (T2))
  • Engagement measures (Up to 6 weeks)
  • Themes From Open-Ended System Usability Scale Responses and Open-Ended Exit Interview Questions (Up to 14 months)
  • Change in fear of progression (At baseline (T1), 6 weeks (T2), and 12 weeks (T3))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2027-02-22
Completion: 2028-01-16
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Anne Reb (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Anne Reb, MD
626-218-4673
areb@coh.org
City of Hope at Arcadia
Anne Reb
626-218-4673
areb@coh.org
City of Hope Medical Center
Anne Reb
City of Hope Medical Center
Interventions
  • Other: Best Practice — Participate in Navigating Cancer Program
  • Other: Interview — Ancillary studies
  • Other: Supportive Care — Participate in Mindful Living Program
  • Other: Supportive Care — Complete skills practice
  • Other: Supportive Care — Receive access to videos and website
Study Locations (11 sites)
City of Hope at Arcadia, Arcadia, California 91007 United States
City of Hope Medical Center, Duarte, California 91010 United States
City of Hope at Seacliff, Huntington Beach, California 92648 United States
City of Hope at Irvine Lennar, Irvine, California 92618 United States
City of Hope Antelope Valley, Lancaster, California 93534 United States
City of Hope at Long Beach Elm, Long Beach, California 90813 United States
City of Hope at Santa Clarita, Santa Clarita, California 91355 United States
City of Hope at Simi Valley, Simi Valley, California 93065 United States
City of Hope at South Pasadena, South Pasadena, California 91030 United States
City of Hope at Upland, Upland, California 91786 United States
Eligibility Criteria
Inclusion Criteria: * Women with stage III or IV GYN (ovarian, endometrial, cervical, vulvar/vaginal) or breast cancer who are at least 2 months from initial diagnosis OR Women with stage I or II endometrial, ovarian, or breast cancer with carcinosarcoma histology OR Women with stage I or II triple negative breast cancer * Score ≥ 34 on the Fear of Progression Short-Form, indicating dysfunctional levels * Age 18 or older; able to read and understand English * Patients can be on active treatment or surveillance. They can be no evidence of disease (NED), recurrent or with progressive disease Exclusion Criteria: * Enrolled in hospice * Ongoing uncontrolled active psychiatric condition that, in the opinion of the investigator, would interfere in the conduct of the study (e.g., mood disorders, psychosis disorders, or substance use), Major depression as assessed by Patient Health Questionnaire-9 (PHQ-9) * Non-English speaking * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics) * Current participation in a mind-body or mindfulness education program within the past six weeks
Conditions Stroke, Post Stroke
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this feasibility study is to test whether a new approach that combines real-time symptom tracking (Ecological Momentary Assessment) with machine learning can help people recovering from a stroke to better manage depression, thinking difficulties, and daily functioning. The main questions it aims to answer are: Is this combined approach practical and acceptable for post-stroke survivors? Does the program improve mood, cognitive function, or functional ability to carry out daily activities? Participants will: Use a smartphone app called RehabCare Companion for a period of time Answer brief daily surveys about their mood, thoughts, and activities for one week Receive personalized self-care suggestions generated by machine learning based on their responses Complete assessments of depression, cognition, and functioning before and after the program Take part in a group interview to share their experiences

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Ecological Momentary Assessment based Self-management Program — The research team collects participants' EMA data (ie., depression, cognitive function, daily activity, and contextual data) from participants for 7-day and analyze the data by machine learning in the first phase, while provide real-time, individualized, self-care messages to the participants via a personalized self-care AI app in the second phase.

Primary Outcomes

  • Feasibility of the study: acceptance (Immediately after the intervention (T2).)
  • Feasibility of the study: adherence (Immediately after the intervention (T2).)
  • Feasibility of the study: experience of the participants in using the app (Immediately after the intervention (T2).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-06
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Hong Kong Polytechnic University
Principal Investigators:
  • Arkers KC Wong, PhD (PRINCIPAL_INVESTIGATOR) - The Hong Kong Polytechnic University
Contact Information
Study Contact:
Arkers KC Prof. Wong, PhD
+852 34003805
arkers.wong@polyu.edu.hk
Nuo Dr. Shi, DHSc
+852 34008172
nuo-catherine.shi@polyu.edu.hk
Vivian WY Ms. Kwok
+852 34003805
arkers.wong@polyu.edu.hk
Queen Elizabeth Hospital
Interventions
  • Behavioral: Ecological Momentary Assessment based Self-management Program — The research team collects participants' EMA data (ie., depression, cognitive function, daily activity, and contextual data) from participants for 7-day and analyze the data by machine learning in the first phase, while provide real-time, individualized, self-care messages to the participants via a personalized self-care AI app in the second phase.
Study Locations (1 sites)
Queen Elizabeth Hospital, Hong Kong, Hong Kong 999077 Hong Kong
Eligibility Criteria
Inclusion Criteria: * adults aged 18 years or older * having a confirmed diagnosis of stroke * having sufficient proficiency in Cantonese to understand and respond to the assessments and prompts * having a Hong Kong version of the Montreal Cognitive Assessment (HK-MoCA) score of 18 or higher * having a smartphone. Exclusion Criteria: * they have moderate to severe cognitive impairment (a HK-MoCA score of 17 or lower) * they have active psychiatric disorders other than depression (e.g., schizophrenia, bipolar disorder) * they have a terminal illness or prognosis that suggests a limited life expectancy * they have conditions that compromise their self-care ability (i.e., bedbound).
Conditions Breast Cancer
Phase PHASE2
Enrollment 98
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of Culmerciclib combined with fulvestrant compared with investigator-selected CDK4/6 inhibitors combined with fulvestrant in patients with HR-positive/HER2-negative breast cancer who have progressed after first-line endocrine therapy

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CDK4/6 inhibitor — investigator's choice of CDK4/6 inhibitor
  • Drug: Culmerciclib — CDK2/4/6 inhibitor
  • Drug: Fulvestrant — Fulvestrant

Primary Outcomes

  • PFS (Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the end of study (approximately 1 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-06-06
Completion: 2029-12-30
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 98 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhimin Shao Professor
08664175590
zhimingshao@yahoo.com
Interventions
  • Drug: CDK4/6 inhibitor — investigator's choice of CDK4/6 inhibitor
  • Drug: Culmerciclib — CDK2/4/6 inhibitor
  • Drug: Fulvestrant — Fulvestrant
Study Locations (1 sites)
Fudan Cancer Center, Shanghai, China
Eligibility Criteria
Inclusion Criteria: * 1\) Female, ≥18 years old; ≤ 75years old 2)ECOG score 0-2; 3) Predicted survival ≥3 months;Patients with locally advanced and/or metastatic breast cancer confirmed by histopathology with positive ER expression and negative HER2 expression; 5) Enrolled subjects must meet one of the following criteria regarding prior endocrine therapy: i) Received CDK4/6 inhibitor combined with endocrine therapy as adjuvant endocrine therapy, experienced recurrence or progression during or within 1 year after completion of adjuvant CDK4/6 inhibitor therapy, and did not receive subsequent endocrine therapy; ii) Recurrence or progression more than 1 year after completion of adjuvant endocrine monotherapy, followed by progression after receiving CDK4/6 inhibitor combined with endocrine therapy as first-line salvage endocrine therapy; iii) Newly diagnosed locally advanced or metastatic disease, with disease progression after receiving CDK4/6 inhibitor combined with endocrine therapy as first-line salvage endocrine therapy; 6)Participants with recurrent or metastatic disease may receive rescue chemotherapy, ADC, or rescue endocrine therapy not exceeding first-line treatment; 7) The time interval between non-endocrine therapy should be ≥2 weeks; 8) At least one extracranial measurable lesion as defined by RECIST V1.1 criteria; 9) The functions of vital organs meet the requirements; 10) Fertile subjects must have a negative pregnancy test 7 days before starting treatment and must use an appropriate contraceptive method during treatment and for three months after completion of treatment; 11) The patient is fully informed and voluntarily signs the informed consent. Exclusion Criteria: * 1\) Previously diagnosed with HER2-positive breast cancer based on pathological testing; ; 2) Known allergy to the tested drug component; 3) inflammatory breast cancer at the time of screening; 4) pia meningeal metastasis confirmed by MRI or lumbar puncture; 5) Central nervous system metastasis confirmed by imaging; 6) To the best of the investigator's judgment, symptomatic visceral disease or any disease load or none is considered optimal Endocrine therapy options are not suitable for endocrine therapy; 7) Inability or unwillingness to swallow medication or receive intramuscular injections; 8) Gastrointestinal insufficiency or gastrointestinal disease (if not controlled) that may significantly affect study drug absorption Ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small intestine resection, etc.; 9) Patients with ascites, pleural effusion and pericardial effusion accompanied by clinical symptoms in the baseline period need drainage, or use it for the first time Patients with serous cavity drainage within 4 weeks before medication; 10) A history of immunodeficiency, including HIV positive, or other acquired or congenital immunodeficiency conditions, Or have a history of organ transplantation; 11) Other malignancies (cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and Thyroid cancer is excluded); 12) had undergone major surgical procedures or significant trauma within 4 weeks prior to the start of treatment, or was expected to undergo major surgery Surgical treatment; 13) Concomitant diseases that, in the investigator's judgment, seriously endanger patient safety or interfere with patient completion of the study (e.g. Severe hypertension, diabetes, thyroid disease, co-active hepatitis B/C, and other activities Sexual infection); 14) Inability to understand or follow research instructions and requirements; 15) The researcher decides that it is not suitable to participate in this study

Parents and Babies Pilot

NCT07607613
Recruiting
Conditions Perinatal Depression, Postpartum Depress...
Phase NA
Enrollment 16
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study will be piloting the Parents and Babies perinatal depression prevention intervention to examine its feasibility and acceptability and to obtain preliminary data on its efficacy. This includes exploring/understanding users' experiences navigating the interventions (e.g., from an implementation perspective) and preliminary evaluations of clinical outcomes, including mental health and minority stress. With data gathered from this pilot study, we will make final adaptations to the Parents and Babies manuals and plan to develop a randomized-control trial to evaluate efficacy of the intervention.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Parents and Babies Virtual Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist.
  • Behavioral: Parents and Babies Hybrid Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist, with an option for in-person participation at three sessions.

Primary Outcomes

  • Patient Health Questionnaire - 9 (PHQ-9) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Perceived Stress Scale (PSS-10) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Generalized Anxiety Disorder Scale (GAD-7) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • Multidimensional Scale of Perceived Social Support (MSPSS) (T1 (prior to starting intervention), T2 (immediately post-intervention), T3 (3 months post-intervention))
  • The Acceptability of Intervention Measure (AIM) (T2 (immediately post-intervention))
  • Intervention Appropriateness Measure (IAM) (T2 (immediately post-intervention))
  • Feasibility of Intervention Measure (FIM) (T2 (immediately post-intervention))
  • Implementation of Parents and Babies skills (T2 (immediately post-intervention), T3 (3-months post-intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-03
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 16 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Northwestern University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Leiszle Lapping-Carr
312- 503-3814
parentsandbabies@northwestern.edu
Northwestern University
Interventions
  • Behavioral: Parents and Babies Virtual Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist.
  • Behavioral: Parents and Babies Hybrid Group Intervention — Parents and Babies is a 10-session intervention adapted from Mothers and Babies, a nationally recognized intervention for depression during pregnancy and postpartum built on principles of cognitive-behavioral therapy (CBT), attachment theory, and psychoeducation. Sessions are delivered virtually and led by a clinical psychologist, with an option for in-person participation at three sessions.
Study Locations (1 sites)
Northwestern University, Chicago, Illinois 60611 United States
Eligibility Criteria
Inclusion Criteria: * self-identify as LGBTQ+ * 18 years old or older * live in the USA or territories * speak and understand English * Currently pregnant or within one year of childbirth * Endorse current mild depressive symptoms or risk factors for postpartum depression Exclusion Criteria: * Are unable to consent/have impaired decision making capacity * Have current active suicidal or homicidal ideation, active psychosis, or current mania * Are currently experiencing a severe depressive episode * Do not have audio and/or video capacity for attending group sessions remotely.
Conditions Type 2 Diabetes, Diabetes Mellitus Type ...
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood sugar control in adults with type 2 diabetes when used in addition to usual stable diabetes treatment. The study will compare the active nutritional product with a matching placebo over 24 weeks. The product was designed using artificial intelligence before the study began, but the same fixed formulation will be used for all participants assigned to the active group. Artificial intelligence will not be used during the study to make individual treatment decisions, adjust dosing, or personalize the product. The main question is whether participants receiving the active product have a greater reduction in HbA1c, a standard marker of average blood sugar levels, from the start of the study to Week 24 compared with participants receiving placebo. The study will also evaluate early blood sugar changes, fasting glucose, body weight and waist measurements in participants with baseline BMI of at least 25.0 kg/m2, safety, hypoglycaemia events, patient-reported outcomes, and gut microbiome features. This is a 100-participant proof-of-concept study intended to estimate the size of the treatment signal, safety, feasibility, and parameters needed for a future larger confirmatory trial.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: Microbiome-targeted oral food supplement — Fixed AI-guided microbiome-targeted oral food supplement administered for 24 weeks. The formulation is fixed and identical for all participants randomized to the active intervention arm. The artificial intelligence methodology was used before the trial for formulation design only and is not used during the trial for participant-level prediction, dosing, clinical decision-making, or formulation adjustment. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
  • Dietary Supplement: Matching placebo oral supplement — Matching placebo oral supplement administered for 24 weeks. The placebo is matched to the active product in appearance, taste, smell, packaging, administration schedule, and storage conditions. The placebo is intended to be microbiome- and glycaemia-neutral and free of active prebiotic, probiotic, synbiotic, postbiotic, glycaemically active, or other bioactive components reasonably expected to affect HbA1c, fasting plasma glucose, body weight, microbiome composition, or inflammatory markers. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.

Primary Outcomes

  • Change in HbA1c from baseline to Week 24 (Baseline to Week 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ENBIOSIS BIOTECHNOLOGIES
Collaborators: Bakırçay University, Faculty of Medicine, Aydin Adnan Menderes University, Buca Seyfi Demirsoy State Hospital, Izmir University of Economics
Principal Investigators:
  • Engin Güney, Prof. Dr. (STUDY_CHAIR) - Aydın Adnan Menderes University Faculty of Medicine Endocrinology Department
  • Varol Tunali, Dr. (PRINCIPAL_INVESTIGATOR) - Enbiosis Biotechnology Limited
Contact Information
Study Contact:
Varol TUNALI, Dr.
+905556303231
vtunali@enbiosis.com
Buğra Yağmur, Mr
+90 505 632 82 82
byagmur@enbiosis.com
Sedat Güney, Dr.
+90 554 844 92 66
sedat.guney@cbu.edu.tr
Bakırçay University Faculty of Medicine Endocrinology Department
Interventions
  • Dietary Supplement: Microbiome-targeted oral food supplement — Fixed AI-guided microbiome-targeted oral food supplement administered for 24 weeks. The formulation is fixed and identical for all participants randomized to the active intervention arm. The artificial intelligence methodology was used before the trial for formulation design only and is not used during the trial for participant-level prediction, dosing, clinical decision-making, or formulation adjustment. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
  • Dietary Supplement: Matching placebo oral supplement — Matching placebo oral supplement administered for 24 weeks. The placebo is matched to the active product in appearance, taste, smell, packaging, administration schedule, and storage conditions. The placebo is intended to be microbiome- and glycaemia-neutral and free of active prebiotic, probiotic, synbiotic, postbiotic, glycaemically active, or other bioactive components reasonably expected to affect HbA1c, fasting plasma glucose, body weight, microbiome composition, or inflammatory markers. Participants also receive identical structured lifestyle counselling and continue stable permitted background glucose-lowering therapy as clinically appropriate.
Study Locations (1 sites)
Bakırçay University Faculty of Medicine Endocrinology Department, Izmir, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: Adults aged 18 to 65 years. Established diagnosis of type 2 diabetes mellitus documented in the medical record, supported by American Diabetes Association diagnostic criteria on at least one prior occasion. HbA1c 6.8% to 8.2% at screening, measured by an NGSP-certified central laboratory assay; confirmed on a repeat sample if discordant with prior records or if the screening value is at the upper or lower boundary. Body mass index 18.5 to 40.0 kg/m2 at screening. Stable background glucose-lowering therapy for at least 3 months before randomization, restricted to metformin, a DPP-4 inhibitor, and/or an SGLT2 inhibitor, either alone or in combination. Documented body-weight stability, defined as no more than +/-5% or +/-3 kg, whichever is smaller, self-reported body-weight change during the 3 months before screening. Willing and able to provide written informed consent. Willing and able to comply with trial visits, study product use, fasting blood sampling, stool sampling, and the study assessment schedule. Willing to receive standardized lifestyle counselling during the 24-week blinded period and to maintain stable background diabetes management as clinically directed. No systemic antibiotic use within 8 weeks before randomization. No probiotic, prebiotic, synbiotic, or postbiotic supplement use within 8 weeks before randomization. Stable hypertension, dyslipidaemia, and stable thyroid replacement therapy are permitted if medication has been initiated and the dose unchanged for at least 3 months before randomization. Exclusion Criteria: Type 1 diabetes, latent autoimmune diabetes of adults, pancreatogenic diabetes, maturity-onset diabetes of the young, gestational diabetes as the current diagnosis, or any non-type-2 form of diabetes. HbA1c less than 6.8% or greater than 8.2% at screening. Current use of GLP-1 receptor agonists or GLP-1/GIP co-agonists, or use within 12 months before randomization. Current use of basal, prandial, or premixed insulin, or any insulin use within 6 months before randomization. Current use of sulfonylureas or meglitinides, or use within 3 months before randomization. Current use of anti-obesity pharmacotherapy or use within 6 months before randomization, including orlistat, naltrexone/bupropion, phentermine/topiramate, or other agents with a primary anti-obesity indication. Recurrent severe hypoglycaemia or hypoglycaemia unawareness. Planned initiation or dose escalation of glucose-lowering medication, anti-obesity medication, or systemic corticosteroids during the 24-week trial period in the judgment of the treating clinician. History of bariatric surgery at any time. Gastrointestinal surgery other than appendectomy or uncomplicated cholecystectomy. Active inflammatory bowel disease, coeliac disease, microscopic colitis, chronic pancreatitis, malabsorption syndrome, or chronic severe gastrointestinal disease likely to affect absorption or trial adherence. Acute gastroenteritis within 4 weeks before randomization. Colonoscopy bowel preparation within 12 weeks before randomization. Faecal microbiota transplantation within 12 months before randomization. Active or recent malignancy within 6 months, except adequately treated non-melanoma skin cancer. Stage 3b to 5 chronic kidney disease, defined as estimated glomerular filtration rate less than 45 mL/min/1.73 m2. Decompensated liver disease or Child-Pugh class B/C. ALT or AST greater than 3 times the upper limit of normal at screening, unless judged clinically insignificant and approved by the investigator. Known or suspected haemoglobinopathy that materially distorts HbA1c measurement or haemoglobin variant known to interfere with the central laboratory assay. Blood transfusion, significant blood loss greater than 250 mL, or erythropoiesis-stimulating agent therapy within 3 months before randomization. Untreated overt thyroid disease, or thyroid medication initiation or dose change within 3 months before randomization. Use of systemic corticosteroids within 4 weeks before randomization. Use of immunosuppressive medication or biologic/immunomodulatory therapy within 5 half-lives before randomization. Pregnancy or lactation; women of childbearing potential not willing to use effective contraception during the 24-week blinded period. Severe psychiatric illness or cognitive impairment that may compromise informed consent, safety, or adherence. Active eating disorder, defined operationally as a positive SCOFF screen with at least 2 affirmative responses at screening, or clinical diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder. Heavy alcohol use or active substance use disorder. Current very-low-calorie diet, ketogenic diet, medically supervised weight-loss diet, or other highly restrictive diet that excludes major food groups. Current cigarette smoking with intention to attempt cessation during the 24-week trial period; current users of nicotine-replacement or smoking-cessation pharmacotherapy initiated within 3 months before randomization. Participation in another interventional clinical trial within 30 days before screening. Known hypersensitivity or clinically significant intolerance to any component of the active product or placebo. Inability or unwillingness to provide stool samples. Any condition that, in the investigator's opinion, would compromise participant safety or trial integrity.